Objective: To compare angiotensin-converting enzyme (ACE) inhibitor use in patients with type 2 diabetes at 1 year and 3 years after guidelines were published. Study Design: Retrospective database ...

Together with researchers from University Hospital Mainz, the University of Regensburg and the IRCM in Montreal (Canada), a research team from Friedrich Schiller University Jena has discovered a novel ...

Glycogen phosphorylase (GP) is a pivotal enzyme responsible for the catabolism of glycogen into glucose, a process intricately linked to blood glucose regulation. In the context of type 2 diabetes, ...

3D structure of a melanoma cell derived by ion abrasion scanning electron microscopy [National Cancer Institute (NCI). Image created by Sriram Subramaniam, NCI] Researchers at Sanford Burnham Prebys ...

Renin–angiotensin system (RAS) inhibitors — including angiotensin-converting–enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) — slow the progression of mild or moderate chronic kidney ...

Molecular Tumor Board–Assisted Care in an Advanced Cancer Population: Results of a Phase II Clinical Trial The development of the selective RET inhibitors selpercatinib and pralsetinib has ...

Objectives: To use a population management strategy to increase the proportion of patients with coronary artery disease (CAD) and diabetes receiving target-dose angiotensin-converting enzyme (ACE) ...

Angiotensin-converting–enzyme (ACE) inhibitors are effective in reducing the risk of heart failure, myocardial infarction, and death from cardiovascular causes in patients with left ventricular ...

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are antihypertensive medicines used to treat high blood pressure. While the enzyme inhibitors work by reducing the level of ...

SGLT2 inhibitors are medications designed to help manage blood sugar in people living with type 2 diabetes. Learn more about the different types, as well as the benefits and side effects.